Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9556690 | 0.90 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6220748 | 0.86 | P2RY2 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL30534780 | 0.82 | DUT (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL5547202 | 0.81 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4074082 | 0.80 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4083099 | 0.80 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4083526 | 0.80 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL5531485 | 0.80 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25233938 | 0.80 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2985708 | 0.80 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284341-B1 | URIDINE TRIACETATE AMORPHOUS FORMULATION | PHARMA CINQ LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12577270-B2 | 2′,3′-diacetyluridine substituted with acetoacetyl at the 5′ position | PHARMA CINQ, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4667478-A1 | 2',3'-DIACETYLURIDINE SUBSTITUTED WITH ACETOACETYL AT THE 5' POSITION | Pharma Cinq, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4210709-B1 | 2',3'-DIACETYLURIDINE SUBSTITUTED WITH ACETOACETYL AT THE 5' POSITION | PHARMA CINQ LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240299434-A1 | URIDINE TRIACETATE AMORPHOUS FORMULATION | PHARMA CINQ, LLC | 2024-09-12 | — | — | US | disclosed |
| EP-4210709-A4 | 2',3'-DIACETYLURIDINE SUBSTITUTED WITH ACETOACETYL AT THE 5' POSITION | Pharma Cinq, LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230357304-A1 | 2′,3′-Diacetyluridine Substituted With Acetoacetyl at the 5′ Position | WELLSTAT THERAPEUTICS CORPORATION | 2023-11-09 | — | — | US | disclosed |
| EP-4210709-A1 | 2',3'-DIACETYLURIDINE SUBSTITUTED WITH ACETOACETYL AT THE 5' POSITION | Wellstat Therapeutics Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-116157133-A | 2',3' -diacetyluridine substituted with acetoacetyl group at 5' position | 维尔斯达医疗公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116157133-A | 2',3' -diacetyluridine substituted with acetoacetyl group at 5' position | 维尔斯达医疗公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20040057962-A1 | Immunogenic complex | BT PHARMA (FR) | 2004-03-25 | — | — | US | disclosed |
| EP-1379280-A2 | IMMUNOGENIC COMPLEX | Timmerman, Benedikt (FR) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002053189-A2 | IMMUNOGENIC COMPLEX | TIMMERMAN BENEDIKT (FR) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577270-B2 | 2′,3′-diacetyluridine substituted with acetoacetyl at the 5′ position | UQCRC2, ACAT1, ACAA2 | SLC28A1 441/4885SLC28A2 268/4885SLC29A1 307/4885 |
| US-20230357304-A1 | 2′,3′-Diacetyluridine Substituted With Acetoacetyl at the 5′ Position | ACAT1, ACADVL, ACAA2 | SLC28A1 1416/4885SLC28A2 1134/4885SLC29A1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.